Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Author:
Funder
Deutsche Forschungsgemeinschaft
Publisher
Korean Association for the Study of Intestinal Diseases
Subject
Gastroenterology
Link
http://www.irjournal.org/upload/pdf/ir-2019-00012.pdf
Reference36 articles.
1. Epidemiology and risk factors for IBD
2. Paneth's disease
3. Enfermedad de Crohn
4. Defective Antibacterial Barrier in Inflammatory Bowel Disease
5. Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis;European Journal of Gastroenterology & Hepatology;2024-02-16
2. Long-term real-world data of ustekinumab in Crohn’s disease: the Stockholm ustekinumab study;Therapeutic Advances in Gastroenterology;2024-01
3. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs;The Korean Journal of Internal Medicine;2022-09-01
4. Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies;Journal of Clinical Medicine;2022-07-20
5. Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis;Journal of Coloproctology;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3